JP6168673B2 - アリールアルキルアミン化合物含有医薬組成物 - Google Patents

アリールアルキルアミン化合物含有医薬組成物 Download PDF

Info

Publication number
JP6168673B2
JP6168673B2 JP2016197725A JP2016197725A JP6168673B2 JP 6168673 B2 JP6168673 B2 JP 6168673B2 JP 2016197725 A JP2016197725 A JP 2016197725A JP 2016197725 A JP2016197725 A JP 2016197725A JP 6168673 B2 JP6168673 B2 JP 6168673B2
Authority
JP
Japan
Prior art keywords
weight
parts
pharmaceutical composition
composition according
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016197725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017071599A (ja
Inventor
村 信 爾 谷
村 信 爾 谷
井 宏 子 吉
井 宏 子 吉
田 見 二 岩
田 見 二 岩
澤 直 人 井
澤 直 人 井
田 元 洋 太
田 元 洋 太
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58538545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6168673(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Priority to KR1020187012497A priority Critical patent/KR102000897B1/ko
Priority to PCT/JP2016/080013 priority patent/WO2017061621A1/ja
Priority to US15/766,426 priority patent/US10350194B2/en
Priority to KR1020197019836A priority patent/KR102488488B1/ko
Priority to CN201680058580.7A priority patent/CN108135883B/zh
Priority to TW109133308A priority patent/TWI808349B/zh
Priority to EP16853772.8A priority patent/EP3360551A4/en
Priority to TW105132660A priority patent/TWI708603B/zh
Publication of JP2017071599A publication Critical patent/JP2017071599A/ja
Publication of JP6168673B2 publication Critical patent/JP6168673B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016197725A 2015-10-07 2016-10-06 アリールアルキルアミン化合物含有医薬組成物 Active JP6168673B2 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201680058580.7A CN108135883B (zh) 2015-10-07 2016-10-07 含有芳基烷基胺化合物的药物组合物
PCT/JP2016/080013 WO2017061621A1 (ja) 2015-10-07 2016-10-07 アリールアルキルアミン化合物含有医薬組成物
US15/766,426 US10350194B2 (en) 2015-10-07 2016-10-07 Pharmaceutical composition containing an arylalkylamine compound
KR1020197019836A KR102488488B1 (ko) 2015-10-07 2016-10-07 아릴알킬아민 화합물 함유 의약 조성물
KR1020187012497A KR102000897B1 (ko) 2015-10-07 2016-10-07 아릴알킬아민 화합물 함유 의약 조성물
TW109133308A TWI808349B (zh) 2015-10-07 2016-10-07 含有芳基烷基胺化合物之醫藥組合物
EP16853772.8A EP3360551A4 (en) 2015-10-07 2016-10-07 PHARMACEUTICAL COMPOSITION WITH ALRYL ALKYLAMINE COMPOUND
TW105132660A TWI708603B (zh) 2015-10-07 2016-10-07 含有芳基烷基胺化合物之醫藥組合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015199694 2015-10-07
JP2015199694 2015-10-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016207285A Division JP2017071605A (ja) 2015-10-07 2016-10-21 アリールアルキルアミン化合物含有医薬組成物

Publications (2)

Publication Number Publication Date
JP2017071599A JP2017071599A (ja) 2017-04-13
JP6168673B2 true JP6168673B2 (ja) 2017-07-26

Family

ID=58538545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016197725A Active JP6168673B2 (ja) 2015-10-07 2016-10-06 アリールアルキルアミン化合物含有医薬組成物
JP2016207285A Pending JP2017071605A (ja) 2015-10-07 2016-10-21 アリールアルキルアミン化合物含有医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016207285A Pending JP2017071605A (ja) 2015-10-07 2016-10-21 アリールアルキルアミン化合物含有医薬組成物

Country Status (6)

Country Link
US (1) US10350194B2 (enExample)
EP (1) EP3360551A4 (enExample)
JP (2) JP6168673B2 (enExample)
KR (1) KR102000897B1 (enExample)
CN (1) CN108135883B (enExample)
TW (2) TWI808349B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100800708B1 (ko) * 2001-09-27 2008-02-01 삼성전자주식회사 키 텔레폰 시스템의 포트 상태 진단 방법
CN108379588B (zh) * 2018-03-05 2024-07-02 合肥合源药业有限公司 托吡酯组合物
WO2020111089A1 (ja) * 2018-11-27 2020-06-04 協和キリン株式会社 医薬組成物
EP4029867A1 (en) * 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
CN115006363A (zh) * 2022-06-23 2022-09-06 上海信谊万象药业股份有限公司 一种牡蛎碳酸钙咀嚼片及其制备方法
JP2024023047A (ja) * 2022-08-08 2024-02-21 日医工株式会社 ビルダグリプチン含有医薬品
CN115381094B (zh) * 2022-08-18 2023-10-24 河南中大恒源生物科技股份有限公司 一种低臭味水溶性叶绿素铜及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4880457A (enExample) 1972-01-31 1973-10-27
JPS5547615A (en) * 1978-09-29 1980-04-04 Taiyo Yakuhin Kogyo Kk Stable solid drug of nifedipine
JP2914690B2 (ja) * 1989-12-13 1999-07-05 グレラン製薬株式会社 安定なビタミンｄ▲下３▼類含有製剤
JP2001233766A (ja) * 2000-11-15 2001-08-28 Ohara Yakuhin Kogyo Kk プラバスタチンナトリウムの錠剤
JP2003104887A (ja) * 2001-09-28 2003-04-09 Maruko Seiyaku Kk 光に安定なアラニジピン含有組成物
ES2299710T3 (es) 2002-08-02 2008-06-01 Ratiopharm Gmbh Preparacion farmaceutica que contiene un compuesto de bencimidazol mezclado con celulosa microcristalina y un metodo para su preparacion.
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
JP4018664B2 (ja) * 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
GB0316206D0 (en) 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
TWI346114B (en) 2003-09-29 2011-08-01 Method for stabilization of diarylvinylene compounds
JP2005154431A (ja) * 2003-11-07 2005-06-16 Takeda Chem Ind Ltd 固形製剤
WO2005044223A1 (en) 2003-11-07 2005-05-19 Takeda Pharmaceutical Company Limited Chewable tablet
JP4783573B2 (ja) * 2004-02-20 2011-09-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ワルファリンカリウム含有医薬組成物とその製造方法
MXPA06012566A (es) * 2004-04-30 2007-05-09 Bkg Pharma Aps Tratamiento de enfermedades infecciosas.
JP4629036B2 (ja) * 2004-05-28 2011-02-09 田辺三菱製薬株式会社 アリールアルキルアミン化合物及びその製法
JP2007032370A (ja) * 2005-07-25 2007-02-08 Aisin Seiki Co Ltd 電動ポンプ
EP1828098A1 (en) * 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
SI1880718T1 (sl) * 2006-07-10 2011-11-30 Pfleger R Chem Fab Farmacevtski pripravki za oralno dajanje z nadzorovanim sproščanjem zdravila v majhne intestinke kolone in postopek njihove priprave
GB0724478D0 (en) 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
WO2010067204A1 (en) * 2008-12-08 2010-06-17 Actavis Group Ptc Ehf Highly pure cinacalcet or a pharmaceutically acceptable salt thereof
WO2010087462A1 (ja) * 2009-01-29 2010-08-05 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
WO2011082980A2 (de) 2009-12-16 2011-07-14 Basf Se Filmüberzugsmittel basierend auf polyvinylalkohol-polyether-pfropfcopolymeren- polyvinylalkohol-kombinationen mit verbesserter feuchtigkeitsbarrierewirkung
JP6133009B2 (ja) 2010-08-11 2017-05-24 協和発酵キリン株式会社 トピラマート顆粒
TWI637943B (zh) * 2013-09-05 2018-10-11 田邊三菱製藥股份有限公司 新穎結晶性芳烷基胺化合物及其製造方法

Also Published As

Publication number Publication date
EP3360551A4 (en) 2019-07-31
TWI808349B (zh) 2023-07-11
TW202110435A (zh) 2021-03-16
US20180296526A1 (en) 2018-10-18
EP3360551A1 (en) 2018-08-15
US10350194B2 (en) 2019-07-16
JP2017071605A (ja) 2017-04-13
CN108135883B (zh) 2021-09-14
TWI708603B (zh) 2020-11-01
TW201717937A (zh) 2017-06-01
CN108135883A (zh) 2018-06-08
KR102000897B1 (ko) 2019-07-16
JP2017071599A (ja) 2017-04-13
KR20180054870A (ko) 2018-05-24

Similar Documents

Publication Publication Date Title
US11007152B2 (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
TWI808349B (zh) 含有芳基烷基胺化合物之醫藥組合物
US10583087B2 (en) Pharmaceutical composition for oral administration
JP2017071605A5 (enExample)
EP4240331B1 (en) Solid formulation
KR20240104205A (ko) 의약품
JP5490347B2 (ja) 経口投与用製剤
KR102488488B1 (ko) 아릴알킬아민 화합물 함유 의약 조성물
JP2017048174A (ja) 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤
JP2013216701A (ja) 経口投与用製剤
CN110494139B (zh) 含有纳呋拉啡的经片剂化的药物组合物
KR20210096162A (ko) 의약 조성물
US9775832B2 (en) Pharmaceutical composition for oral administration
JP2022151564A (ja) 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤
JP2026009040A (ja) 医薬組成物
TR2021001943A2 (tr) Emoksi̇pi̇n i̇çeren bi̇r fi̇lm kapli tablet
HK40058353A (en) Pharmaceutical composition
WO2018110683A1 (ja) 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
JP2012012411A (ja) 経口投与用製剤
JP2012041290A (ja) ラフチジン含有固形製剤

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170623

R150 Certificate of patent or registration of utility model

Ref document number: 6168673

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250